Cardiff Oncology Inc (CRDF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2014 | 12-2013 | 12-2012 | 12-2011 | 12-2006 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 27,294 | 25,837 | 10,820 | 700 | 470 |
| Receivables | 57 | 79 | 168 | 99 | 0 |
| Other current assets | 0 | 0 | 0 | 0 | 20 |
| TOTAL | $27,720 | $26,069 | $11,048 | $842 | $490 |
| Non-Current Assets | |||||
| PPE Net | 840 | 751 | 255 | 23 | 90 |
| Other Non-Current Assets | 337 | 336 | 362 | 175 | 50 |
| TOTAL | $1,177 | $1,087 | $617 | $197 | $140 |
| Total Assets | $28,897 | $27,156 | $11,665 | $1,039 | $640 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 1,899 | 198 | N/A | N/A | 0 |
| Accounts payable and accrued liabilities | 748 | 287 | 176 | 928 | 500 |
| Accrued Expenses | 1,842 | 1,524 | 555 | 502 | 0 |
| TOTAL | $4,488 | $2,009 | $730 | $1,430 | $500 |
| Non-Current Liabilities | |||||
| Long Term Debt | 13,053 | 323 | N/A | N/A | 0 |
| Other Non-Current Liabilities | 3,006 | 4,432 | 8,766 | 3,841 | 110 |
| TOTAL | $16,059 | $4,755 | $8,766 | $3,841 | $110 |
| Total Liabilities | $20,547 | $6,764 | $9,496 | $5,271 | $620 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 335 | 262 | 217 | N/A | N/A |
| Common Shares | 2 | 2 | 2 | 1 | 2 |
| Retained earnings | -81,392 | -67,043 | -55,203 | -43,598 | -20,590 |
| Other shareholders' equity | 0 | 0 | 0 | 0 | 1,058 |
| TOTAL | $8,350 | $20,392 | $2,169 | $-4,231 | $20 |
| Total Liabilities And Equity | $28,897 | $27,156 | $11,665 | $1,039 | $640 |